HOME >> MEDICINE >> NEWS
Cervical cancer A single vaccine could benefit most women

Copenhagen, Denmark: The risk of developing cervical cancer by women infected with the Human Papillomavirus (HPV) is essentially the same no matter which type of virus is involved, provided it belongs to the group of 15 or so that are currently identified as high risk, a scientist said today.

Speaking at ECCO 12 The European Cancer Conference in Copenhagen, Dr. Xavier Bosch, of the Institut Catal d'Oncologia, Barcelona, Spain, said that testing with a cocktail of the majority of high risk type virus would provide a sufficient answer for clinical guidance, and be important to the success of any future screening or vaccination programmes.

HPV is an extremely common sexually transmitted infection. In many cases the infections are harmless and go away without the need for treatment.

But persistent infection with certain types of HPV increases the risk of cervical cancer. These types can be detected in 90-100% of cases of cervical cancer, as opposed to 5-20% of controls. These types are believed to be a necessary cause of cervical cancer and this provides a strong rationale for their use in screening and for the development of anti-HPV vaccines.

"Women who are not infected persistently with one of the cancer-causing types of HPV do not develop cervical cancer", said Dr. Bosch, "and this knowledge is helping us develop effective prevention programmes."

Dr. Bosch and colleagues derived their specific risk estimates from studying a pool of evidence collected by IARC, the International Agency for Research on Cancer, based in Lyon, France. In Europe it is estimated that 65000 new cases of cervical cancer are diagnosed each year, of which 21000 eventually lead to death. HPV carriers are typically young and sexually active, and evidence suggests that males and females are equally likely to be carriers. "In Europe and North America a vaccine including HPV 16 and 18 the most common high risk types of the virus would prevent 72% of ca
'"/>

Contact: Margaret Willson
45-3252-3383
Federation of European Cancer Societies
22-Sep-2003


Page: 1 2

Related medicine news :

1. Cervical cancer treatment depends on patient age
2. Cervical cancer vaccine may lose effectiveness during ovulation
3. Cervical tissue changes may explain false negative pap smears
4. Further Evidence On The Effect Of The UK Cervical Screening Programme
5. Cervical Screening Has Reduced Incidence And Mortality From Cervical Cancer
6. Vinegar Offers Dependable Test For Cervical Cancer
7. Women Who Have Invasive Cervical Cancer Benefit From Addition Of Chemotherapy To Radiation Treatment
8. Hormonal treatment improves survival in high-risk prostate cancer patients
9. International breast cancer prevention study launches in the United States and Canada
10. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
11. Cultural and social factors influence prostate cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: